The Awards ceremony will be preceded by a panel discussion on ‘From Volumes to Value Play: Towards Achieving Vision 2020’
UBM India has announced the second edition of its annual India Pharma Awards which is schedule to be held on 1st December 2014 at The Westin Hotel, Mumbai. The Awards ceremony will be preceded by a panel discussion on ‘From Volumes to Value Play: Towards Achieving Vision 2020’.
Recognising leading innovators across nine categories, the India Pharma Awards acknowledge innovation and excellence in the Indian pharmaceutical industry, thus creating an industry platform to celebrate the contribution of its key players amongst their Indian and international fraternity.
Against the backdrop of the global pharma industry increasingly looking at India for higher quality and low cost pharma solutions, the India Pharma Awards celebrate the thinkers and creators who consistently break new ground in the pharma sector thereby taking the value chain to its next level.
Ernst & Young is the process adviser for the event. The jury panel for 2014 India Pharma Awards will be chaired by: Dr Sudarshan Jain, Managing Director, Abbott Healthcare Solutions, Dr Ajit Dangi, President and CEO, Danssen Consulting, Dr Safia Rizvi, Managing Director, UCB India, Devinder Pal, President, Catalyst Pharma Consulting and S V Veerramani, Founder and Chairman, Fourrts (India) and President, IDMA.
Joji George, Managing Director, UBM India said, “The consent of such an esteemed panel to be associated with the awards, further validates the industry need and acceptance of such a platform in India, to acknowledge and recognise the contribution of pharma companies.”
During the panel discussion, panellists will deliberate on the factors holding back the Indian pharma industry, from transitioning from a volumes to a value play and also give their recommended strategies for success. The session will proceed with panellists like Dr Ajit Dangi, President and CEO, Danssen Consulting; DG Shah, Secretary General, Indian Pharmaceutical Alliance (IPA); Ramesh Swaminathan. Chief Financial Officer, Lupin Pharma; and Kewal Handa, Founder Chairman, Salus Lifecare and the discussion will be moderated by Viveka Roychowdhury, Editor, Express Pharma, Financial Express-B2B. The panel discussion aims to provide new insights to the strategy tool kit of pharma industry professionals.
Reliance Commercial Finance is the event’s Presenting Partner for the 2014 edition of India Pharma Awards. Its gold partner for the event is the prestigious UK Trade and Investment (UKTI). Other partners include: Airline Partner- Qatar Airways, Category Partner- International Biotech Park, Knowledge Partner – Express Pharma, Official Partner – Microsoft mobile devices and services and Gifting Partner – Giftxoxo.com.
The award ceremony will precede the much awaited three days pharma sector event, CPhI/ P-MEC India 2014 which is organised by UBM India. The event is considered as a mega event in India in a platform wherein key players of the pharma sector, worldwide, will congregate to connect, share and ideate.
The event which will be attended by more than 300 decision makers from across the industry; India’s pharma machinery, technology, ingredients, outsourcing and bio-pharma industry, will also witness participation of key officials from the ministries (Home, Food & Drug Dept).
P-MEC India, co-located with CPhI India and in its eighth year, provides the industry with an international platform to showcase pharma equipment, machinery and technology to a forum of decision makers from across the world. Additionally, ICSE India has rapidly gained a positive reputation in the market by offering direct access to the outsourcing and contract services sector which is one of the fastest growing segments within the Indian pharma industry.
At CPhI India 2014, UBM will also release Comprehensive India Pharma Report, conducted with the help of research partner Global Business Reports. The report would analyse trends from leading Indian pharma players and forecast new markets and growth areas in a region predicted by analysts to reach $45 billion by 2020.
EP News Bureau– Mumbai